SCYX
SCYNEXIS, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.30
−0.84%Year over year
Reported trailing growth
- Revenue
- +489.8%
- EBITDA
- +44.7%
- EBIT
- +38.2%
- EPS
- +15.1%
- Free cash flow
- +44.8%
- Operating cash flow
- +44.8%
Forward estimates
Based on analyst estimates
- Revenue
- -93.2%
- EBITDA
- —
- EPS
- -84.5%
Three-year CAGR
- Revenue
- +59.4%
- EBITDA
- +56.3%
- EBIT
- +56.7%
- Net income
- +59.6%
- EPS
- +60.7%
- Free cash flow
- +78.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026